J&J: FDA approves new MS treatment
(CercleFinance.com) - Johnson & Johnson announced Friday that the US FDA has approved Ponvory, its new treatment for multiple sclerosis (MS).
The once-daily oral tablet, chemically known as ponesimod, has been approved for the treatment of the most common form of the disease - relapsing-remitting multiple sclerosis.
J&J points out that the drug, which was developed by its biopharmaceutical subsidiary Janssen, has a safety profile backed by over 10 years of clinical research.
In phase 3 trials, 71% of patients treated with Ponnvory had no relapse of the disease over a two-year period, compared to 61% in the Aubagio group (Sanofi Genzyme).
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The once-daily oral tablet, chemically known as ponesimod, has been approved for the treatment of the most common form of the disease - relapsing-remitting multiple sclerosis.
J&J points out that the drug, which was developed by its biopharmaceutical subsidiary Janssen, has a safety profile backed by over 10 years of clinical research.
In phase 3 trials, 71% of patients treated with Ponnvory had no relapse of the disease over a two-year period, compared to 61% in the Aubagio group (Sanofi Genzyme).
Copyright (c) 2021 CercleFinance.com. All rights reserved.